At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AMGN Amgen
Not Yet Opened 12-22 16:00:00 EST
331.39
+4.01
+1.22%
盘后331.39
+0.000.00%
19:46 EST
High331.88Low326.08Vol2.40M
Open327.01D1 Closing327.38Amplitude1.77%
Mkt Cap178.45BTradable Cap177.95BTotal Shares538.48M
T/O794.35MT/O Rate0.45%Tradable Shares536.99M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Assessing Amgen (AMGN) Valuation After UPLIZNA Approval and New U.S. Drug Pricing Agreements
Simply Wall St.  ·  12-22 01:14
Assessing Amgen (AMGN) Valuation After UPLIZNA Approval and New U.S. Drug Pricing Agreements
Merck (MRK.US), Bristol-Myers Squibb (BMY.US), and Other Pharma Giants Agree to Lower U.S. Drug Prices in Exchange for Tariff Exemptions and Policy Support
Stock News  ·  12-20
Merck (MRK.US), Bristol-Myers Squibb (BMY.US), and Other Pharma Giants Agree to Lower U.S. Drug Prices in Exchange for Tariff Exemptions and Policy Support
Trump, Nine Pharmaceutical Companies Strike Deal to Cut Prices
Reuters  ·  12-20
Trump, Nine Pharmaceutical Companies Strike Deal to Cut Prices
Shares of Some U.S. Drugmakers Rise After Signing Drug Pricing Deal With President Trump
THOMSON REUTERS  ·  12-20
Shares of Some U.S. Drugmakers Rise After Signing Drug Pricing Deal With President Trump
Shares of Bristol Myers Squibb up 1.8%, Gilead Sciences up 2.9%, Amgen and Merck up Nearly 1%
THOMSON REUTERS  ·  12-20
Shares of Bristol Myers Squibb up 1.8%, Gilead Sciences up 2.9%, Amgen and Merck up Nearly 1%
Amgen to Cut US Drug Prices, Expand Patient Access
MT Newswires Live  ·  12-20
Amgen to Cut US Drug Prices, Expand Patient Access
BRIEF-Amgen Says Aimovig & Amjevita To Be Available At Discounted Monthly Price Of $299 Under Deal With U.S. Govt
Reuters  ·  12-20
BRIEF-Amgen Says Aimovig & Amjevita To Be Available At Discounted Monthly Price Of $299 Under Deal With U.S. Govt
Trump Reportedly Strikes Drug Price Deals With 9 Pharma Companies
MT Newswires Live  ·  12-20
Trump Reportedly Strikes Drug Price Deals With 9 Pharma Companies
Trump: the 3 of the 17 Pharmaceutical Companies Who Have Not Agreed Are Coming in Next Week
THOMSON REUTERS  ·  12-20
Trump: the 3 of the 17 Pharmaceutical Companies Who Have Not Agreed Are Coming in Next Week
Amgen Inc: All Three Medicines Will Also Be Offered Through Trumprx.gov.
THOMSON REUTERS  ·  12-20
Amgen Inc: All Three Medicines Will Also Be Offered Through Trumprx.gov.
Amgen Takes Action With the U.S. Government to Lower the Cost of Medicines for American Patients
THOMSON REUTERS  ·  12-20
Amgen Takes Action With the U.S. Government to Lower the Cost of Medicines for American Patients
Amgen Inc - Invested Over $40 Bln in Manufacturing and R&D Since 2018
THOMSON REUTERS  ·  12-20
Amgen Inc - Invested Over $40 Bln in Manufacturing and R&D Since 2018
Amgen Inc - Expand Its Direct-to-Patient Program, Amgennow™ to Include Aimovig(®) (Erenumab-Aooe) and Amjevita(®) (Adalimumab-Atto)
THOMSON REUTERS  ·  12-20
Amgen Inc - Expand Its Direct-to-Patient Program, Amgennow™ to Include Aimovig(®) (Erenumab-Aooe) and Amjevita(®) (Adalimumab-Atto)
Amgen Inc: Aimovig & Amjevita Will Be Available at a Discounted Monthly Price of $299
THOMSON REUTERS  ·  12-20
Amgen Inc: Aimovig & Amjevita Will Be Available at a Discounted Monthly Price of $299
Several Manufacturers Agree to Donate Active Pharmaceutical Ingredients to U.S. Strategic Reserve -U.S. Official
THOMSON REUTERS  ·  12-20
Several Manufacturers Agree to Donate Active Pharmaceutical Ingredients to U.S. Strategic Reserve -U.S. Official
Companies Agree to Sell All Future Drugs at Most Favored Nation Prices -U.S. Official
THOMSON REUTERS  ·  12-20
Companies Agree to Sell All Future Drugs at Most Favored Nation Prices -U.S. Official
14 of 17 Leading Drug Manufacturers NOW Part of Trump Administration’s Most Favored Nation Initiative -U.S. Official
THOMSON REUTERS  ·  12-20
14 of 17 Leading Drug Manufacturers NOW Part of Trump Administration’s Most Favored Nation Initiative -U.S. Official
Companies Will Offer Many Drugs Direct-to Consumer at Lower Prices Through Trumprx Website -U.S. Official
THOMSON REUTERS  ·  12-20
Companies Will Offer Many Drugs Direct-to Consumer at Lower Prices Through Trumprx Website -U.S. Official
Deals Are With Amgen, Bristol Myers Squibb, Roche’s Genentech, Gilead, GSK, Merck, Novartis, Sanofi and Boehringer Ingelheim -U.S. Official
THOMSON REUTERS  ·  12-20
Deals Are With Amgen, Bristol Myers Squibb, Roche’s Genentech, Gilead, GSK, Merck, Novartis, Sanofi and Boehringer Ingelheim -U.S. Official
Trump to Announce Deals With Nine Pharmaceutical Companies to Reduce Drug Prices -Senior Administration Official
THOMSON REUTERS  ·  12-20
Trump to Announce Deals With Nine Pharmaceutical Companies to Reduce Drug Prices -Senior Administration Official

Introduction

Company Name.
Amgen
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Issue price:
--